On August 4, Huadong Medicine Co., Ltd. (Stock Code: 000963.SZ, hereinafter referred to as "Huadong Medicine") announced that its wholly-owned subsidiary, Huadong Medicine (Hangzhou) Co., Ltd., has reached a commercialization collaboration in mainland China with Beijing Yimiao Shenzhou Medical Technology Co., Ltd. (hereinafter referred to as "Yimiao Shenzhou"), an innovative company primarily focused on the research and development of CAR-T cell therapies for hematological malignancies and solid tumors. The collaboration concerns IM19 Chimeric Antigen Receptor T-cell Injection (hereinafter referred to as “IM19 Injection”), Yimiao Shenzhou's autologous CAR-T candidate product targeting CD19.1.25 Billion Yuan! CARsgen Therapeutics and Huadong Medicine Reach Commercialization Collaboration on Zevor-cel）
IM19 Injection, as the leading pipeline product of Beijing Yimiaoshenzhou Medical Technology Co., Ltd., is currently being developed in China for diffuse large B-cell lymphoma, mantle cell lymphoma, andAcute B Lymphoblastic LeukemiaClinical studies on three indications. The research targeting end-line treatment for diffuse large B-cell lymphoma is about to complete Phase II clinical trials (confirmatory clinical trial) in 2024. Based on this collaboration, Huadong Medicine will obtain exclusive commercial rights to IM19 injection in mainland China. The authorized scope covers the treatment of all B-cell hematological tumors, including relapsed or refractory diffuse large B-cell lymphoma, acute B lymphoblastic leukemia, and mantle cell lymphoma.Founder, Chairman, and Chief Executive Officer of Yimiao ShenzhouHe TingPh.D.Stated: "We are highly honored to establish a partnership with Huadong Medicine, marking a solid step forward in Yimiao Shenzhou’s commercialization journey of our self-developed CAR-T drugs. Huadong Medicine possesses extensive commercialization experience in mainland China and the strategic goal of becoming a leading pharmaceutical company in the field of oncology treatment, laying a strong foundation for a powerful and mutually beneficial strategic partnership between both parties. We are confident that through this collaboration, leveraging the leading product advantages of IM19 injection and Huadong Medicine's robust commercialization capabilities, we will further accelerate the commercialization process of IM19 injection in China, effectively meeting the significant clinical needs for B-cell hematological malignancies in China."Lü Liang, Chairman and General Manager of Huadong MedicineStated: "Beijing Yimiaoshenzhou Medical Technology Co., Ltd. is a leader in cell therapy within the oncology field, possessing core technologies that cover the entire process of gene and cell drug research, development, and production. The oncology field is one of Huadong Medicine's strategic focus areas, achieving a leading 'multi-cancer type + multi-therapy' layout covering both solid tumors and hematological malignancies, with a strong market service team already established in the area of hematological tumor cell therapy. We are delighted to collaborate with Beijing Yimiaoshenzhou Medical Technology Co., Ltd. to oversee the commercialization of IM19 injection in mainland China. As a highly promising CAR-T product, IM19 injection will provide new treatment options for patients with diffuse large B-cell lymphoma, extending survival and improving quality of life. This will further enrich Huadong Medicine’s product portfolio in the field of blood disorders, creating effective synergy with existing products."According to the terms of the agreement, Beijing Yimiaoshenzhou Medical Technology Co., Ltd. will receive an upfront payment of 125 million RMB and is eligible to receive registration and sales milestone payments of up to 950 million RMB. Beijing Yimiaoshenzhou Medical Technology Co., Ltd. will continue to be responsible for the development, registration, and production of IM19 injection in mainland China.
Follow the official account below to explore the world with you!
